HSMD

Indication Expansion and Repurposing of PIK3CA Kinase Inhibitors: Systems Analysis of Alpelisib and Oral Cancers

154 views
September 20, 2023

Here we demo tools to rapidly guide drug repurposing and indication expansion, using alpelisib—a PI3Kα inhibitor approved for metastatic breast cancer—as a case study. The speaker shows how activating mutations in the PIK3CA gene, a key oncogene, not only prevalent in breast cancer but also significantly present in oral cancers, an area with few active clinical trials and limited therapeutic development. By merging real-world mutation data, clinical outcomes, and pathway-based network modeling, the analysis shows that PIK3CA mutations in oral cancer correlate with poorer survival, and that inhibiting PIK3CA activity could reduce disease progression. Further, the session used public dataset comparisons to identify non-oncologic diseases (e.g., lupus, heart disease) that share similar biology, suggesting future repurposing potential. It concluded by identifying possible combination therapy partners through anti-matching expression patterns, showcasing a full workflow from hypothesis generation to target validation in under an hour.

Related videos

Gene Variant Databases

Access to real-world data and 2 decades of expert curation

2,791 views October 01, 2021

Across oncology applications, from research to molecular testing and...

Gene Variant Databases

Identify meaningful mutations in somatic tumor testing

1,456 views February 14, 2022

From Information Overload to Actionable Insights Precision medicine is...

HSMD

Target discovery through QIAGEN IPA and HSMD

556 views May 13, 2022

Identifying and studying the genomic characteristics of drug targets and...

Gene Variant Databases

How to simplify somatic NGS analysis & reduce literature review time by 90% with HSMD

534 views March 29, 2023

Across clinical oncology applications, from molecular testing to cancer...